/https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/38602414/38602414-1710163512282-a7c132e056a57.jpg)
Flot.bio x Philip Hemme
Flot.bio
Building a Liposome Biotech without VCs | Stefan Halbherr, InnoMedica | E64 [Sponsored]
NOV 12, 202671 MIN
/https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/38602414/38602414-1794468171952-c62393b6f8cc9.jpg)
Description
Nanomedicines specialist InnoMedica began in the cellar of an office building for two years before building its own nanofactory near Fribourg.Stefan and I talked about how InnoMedica’s liposome platform breathes new life into generic drugs, the Phase 1 trial of its liposomal GM1 candidate for Parkinson’s, and the company’s VC-free financing structure.We also covered why he looks to Elon Musk, Moderna and BioNTech for inspiration, and what pharma can learn from the tech industry.---
For transparency, this episode has been sponsored by InnoMedica. Learn more here: https://bit.ly/4AnPF5o
---
Discover the best biotech companies in 🇪🇺 with the FlotBio Map at https://bit.ly/4nXmKjN
---
⭐️ ABOUT THE SPEAKER
Stefan Halbherr has been part of InnoMedica since its founding in 2013. He has a Master’s in Biochemistry and Immunology and a PhD from the University of Bern, Switzerland.
🔗 LINKS MENTIONED
InnoMedica team page — innomedica.com
Eroom’s law and the decline in the productivity of biopharmaceutical R&D, OECD — oecd.org
Gunilla Osswald, BioArctic, Flot.bio E26 — flot.bio
Noboru Yamazaki, Yamazaki Drug Delivery Systems — equilar.com
Aspen Neuroscience prices Nasdaq IPO at $15 a share, $140.6M — lw.com
Sumitomo Pharma, Amchepry approval in Japan (March 6, 2026) — sumitomo-pharma.com
Daniela Marino, CUTISS, Flot.bio E42 — flot.bio
Sean Marett, BioNTech, Flot.bio E25 — flot.bio
Stephane Bancel, Moderna, Flot.bio E35 — flot.bio
📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/stefan-halbherr-innomedica-nanomedicine/
💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
Newsletter: http://eepurl.com/h_fnmH
LinkedIn: https://www.linkedin.com/company/flot-bio/
X (Twitter): https://x.com/FlotBio
🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.
⏰ TIMESTAMPS
[00:00:00] Intro
[00:02:31] Why InnoMedica Built Its Own Nanofactory
[00:06:12] How The Liposome Platform Solves Pharma’s Drug Delivery Challenge
[00:11:38] Clinical Phase 1 Results and GM1 Ganglioside
[00:21:31] Crossing The Blood–Brain Barrier
[00:27:23] The Clinical Trial Timeline
[00:39:28] Financing Without VCs: Partnering, Licensing and IPO
[00:47:43] Cash Flow and the New Raise
[00:54:30] Beginning in the Cellar: How Stefan Halbherr Launched InnoMedica
[01:02:43] Love What You Do, and Cultivating Emotional Intelligence
[01:06:42] Quick-Fire Questions

